Pitiríase versicolor

Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. Resumo

Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9.

1. Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82. Resumo

2. Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006 Apr;19(2):139-47. Resumo

3. Aljabre SH, Alzayir AA, Abdulghani M, et al. Pigmentary changes of tinea versicolor in dark-skinned patients. Int J Dermatol. 2001 Apr;40(4):273-5. Resumo

4. Maymone MBC, Watchmaker JD, Dubiel M, et al. Common skin disorders in pediatric skin of color. J Pediatr Health Care. 2019 Nov-Dec;33(6):727-37.Texto completo  Resumo

5. Kallini JR, Riaz F, Khachemoune A. Tinea versicolor in dark-skinned individuals. Int J Dermatol. 2014 Feb;53(2):137-41. Resumo

6. Pontasch MJ, Kyanko ME, Brodell RT. Tinea versicolor of the face in black children in a temperate region. Cutis. 1989 Jan;43(1):81-4. Resumo

7. Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33. Resumo

8. Moseley I, Ragi SD, Ouellette S, et al. Tinea versicolour in underrepresented groups: an All of Us database analysis. Skin Health Dis. 2022 Jul 21;3(1):e152.Texto completo  Resumo

9. Odland GF, Kraning KK. Prevalence, morbidity, and cost of dermatological diseases (editorial). J Invest Dermatol. 1979;73(5):395-401.Texto completo  Resumo

10. Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol. 1981 Nov;117(11):752-3.

11. Balestri R, Rech G, Piraccini BM, et al. Pityriasis versicolor during anti-TNF-α monoclonal antibody therapy: therapeutic considerations. Mycoses. 2012 Sep;55(5):444-6. Resumo

12. Morishita N, Sei Y. Microreview of pityriasis versicolor and Malassezia species. Mycopathologia. 2006 Dec;162(6):373-6. Resumo

13. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004 Nov;51(5):785-98. Resumo

14. Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78. Resumo

15. Conklin RJ. Common cutaneous disorders in athletes. Sports Med. 1990 Feb;9(2):100-19. Resumo

16. Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in culture of Pityrosporum. J Invest Dermatol. 1978 Sep;71(3):205-8. Resumo

17. De Luca C, Picardo M, Breathnach A, et al. Lipoperoxidase activity of Pityrosporum: characterisation of by-products and possible role in pityriasis versicolor. Exp Dermatol. 1996(Feb);5(1):49-56. Resumo

18. Karaoui R, Bou-Resli M, Alzaid NS, et al. Tinea versicolor: ultrastructural studies on hypopigmented and hyperpigmented skin. Dermatologica. 1981;162(2):69-85. Resumo

19. Borgers M, Cauwenbergh G, Van De Ven M, et al. Pityriasis versicolor and Pityrosporum ovale: morphogenetic and ultrastructural considerations. Int J Dermatol. 1987 Nov;26(9):586-9. Resumo

20. Thoma W, Kramer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):147-52. Resumo

21. Allen HB, Charles CR, Johnson BL. Hyperpigmented tinea versicolor. Arch Dermatol. 1976 Aug;112(8):1110-2. Resumo

22. Galdari I, El Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol. 1992 Apr;31(4):253-6. Resumo

23. Dotz WI, Henrickson DM, Yu GS, et al. Tinea versicolor: a light and electron microscopic study of hyerpigmented skin. J Am Acad Dermatol. 1985 Jan;12(1 Pt 1):37-44. Resumo

24. Kamalam A, Thambiah AS, Bagavandas M, et al. Mycosis in India: study in Madras. Trans R Soc Trop Med Hyg. 1981;75(1):92-100. Resumo

25. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80. Resumo

26. Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica. 1985;171(2):86-8. Resumo

27. He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses. 2008 Jan;51(1):55-62.Texto completo  Resumo

28. Stein DH. Superficial fungal infections. Pediatr Clin North Am. 1983 Jun;30(3):545-61.

29. Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):300-5. Resumo

30. Lohoue Petmy J, Lando AJ, Kaptue L, et al. Superficial mycoses and HIV infection in Yaounde. J Eur Acad Dermatol Venereol. 2004 May;18(3):301-4. Resumo

31. Han A, Calcara DA, Stoecker WV, et al. Evoked scale sign of tinea versicolor. Arch Dermatol. 2009 Sep;145(9):1078.

32. Spence-Shishido A, Carr C, Bonner MY, et al. In vivo Gram staining of tinea versicolor. JAMA Dermatol. 2013 Aug;149(8):991-2.Texto completo

33. Stamm LV. Pinta: Latin America's forgotten disease? Am J Trop Med Hyg. 2015 Nov;93(5):901-3.Texto completo  Resumo

34. Yang S, Makredes M, O'Donnell P, et al. A case of Hansen Disease presenting as tinea versicolor. Dermatol Online J. 2013 Apr 15;19(4):7.Texto completo  Resumo

35. El-Gothamy Z, Abdel-Fattah A, Ghaly AF. Tinea versicolor hypopigmentation: histochemical and therapeutic studies. Int J Dermatol. 1975 Sep;14(7):510-5. Resumo

36. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy. 1999 May;54(5):413-9.Texto completo

37. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9.

38. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. Resumo

39. Mills OH Jr, Kligman AM. Letter: tretinoin in tinea versicolor. Arch Dermatol. 1974 Oct;110(4):638.

40. Shi TW, Ren XK, Yu HX, et al. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012;224(2):184-8. Resumo

41. Wedig JH, Kennedy GL Jr, Jenkins DH, et al. Teratologic evaluation of dermally applied zinc pyrithione on swine. Toxicol Appl Pharmacol. 1976 May;36(2):255-9.

42. Nolen GA, Patrick LF, Dierckman TA. A percutaneous teratology study of zinc pyrithione in rabbits. Toxicol Appl Pharmacol. 1975 Mar;31(3):430-3. Resumo

43. Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002 Dec;13(4):185-7. Resumo

44. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr;18(2):79-90. Resumo

45. Köse O, Bülent Taştan H, Riza Gür A, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat. 2002 Jun;13(2):77-9. Resumo

46. Wahab MA, Ali ME, Rahman MH, et al. Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J. 2010 Jan;19(1):72-6. Resumo

47. Medicines and Healthcare Products Regulatory Agency. Press release: oral ketoconazole-containing medicines should no longer be used for fungal infections. July 2013 [internet publication].Texto completo

48. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013 [internet publication].Texto completo

49. US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. May 2016 [internet publication].Texto completo

50. Helou J, Obeid G, Moutran R, et al. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014 Feb;53(2):e114-6.

51. Faergemann J, Djarv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis. 1982 Oct;30(4):542-5;550.

52. Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis. 1984 Nov;34(5):470-1. Resumo

53. Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002 Jan;138(1):69-73.Texto completo  Resumo

54. Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4.